Kalaris Therapeutics, Inc. announced positive additional data from its Phase 1a single ascending dose clinical trial of TH103 in treatment-naïve patients with neovascular age-related macular degeneration. The expanded dataset includes 17 treatment-naïve patients and 3 treatment-experienced patients, showing a9.2-letter mean BCVA improvement at one month and a 118µm mean CST improvement. Pharmacokinetic findings suggest greater intraocular retention compared to leading anti-VEGF agents. The company is actively enrolling and dosing patients in its ongoing Phase 0.5 Phase 1b/2 study, with preliminary data expected in the1H 2027. Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on retinal disease treatments.
